Lv3
358 积分 2025-12-13 加入
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib
2个月前
已完结
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials
3个月前
已关闭
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
3个月前
已完结
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
3个月前
已关闭
Guest editorial
3个月前
已完结
August 2025 data-update for "Updated science-wide author databases of standardized citation indicators"
3个月前
已完结
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
3个月前
已完结
Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
3个月前
已完结
Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review
3个月前
已完结
皖公网安备34019202002308
